These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 27222030)

  • 21. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
    Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
    BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
    Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy.
    Shimodaira K; Nakashima J; Nakagami Y; Hirasawa Y; Hashimoto T; Satake N; Gondo T; Namiki K; Ohori M; Ohno Y
    Urol J; 2020 Jan; 17(1):42-49. PubMed ID: 30882158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Hematologic and Other Prognostic Markers in Metastatic Colorectal Cancer.
    Mercier J; Voutsadakis IA
    J Gastrointest Cancer; 2019 Sep; 50(3):493-506. PubMed ID: 29704170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With
    Kobayashi T; Namitome R; Hirata YU; Shiota M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2019 Jun; 39(6):3191-3195. PubMed ID: 31177166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma.
    Li X; Chen ZH; Xing YF; Wang TT; Wu DH; Wen JY; Chen J; Lin Q; Dong M; Wei L; Ruan DY; Lin ZX; Wu XY; Ma XK
    Tumour Biol; 2015 Apr; 36(4):2263-9. PubMed ID: 25409616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer.
    Lian L; Xia YY; Zhou C; Shen XM; Li XL; Han SG; Zheng Y; Mao ZQ; Gong FR; Wu MY; Chen K; Tao M; Li W
    Cancer Biomark; 2015; 15(6):899-907. PubMed ID: 26444485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
    Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Platelet to lymphocyte ratio in peripheral blood and body mass index: novel independent prognostic factors in patients with melanoma].
    Qi YL; Zhang Y; Zhao LD; Wang AX; Wang ZB; Gao QL
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3704-3710. PubMed ID: 29325323
    [No Abstract]   [Full Text] [Related]  

  • 32. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
    Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
    Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
    World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios on Survival in Patients with Extrahepatic Cholangiocarcinoma.
    Kitano Y; Yamashita YI; Yamamura K; Arima K; Kaida T; Miyata T; Nakagawa S; Mima K; Imai K; Hashimoto D; Chikamoto A; Baba H
    Anticancer Res; 2017 Jun; 37(6):3229-3237. PubMed ID: 28551669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of Platelet-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio as a New Promising Prognostic Factor in Upper Tract Urothelial Carcinoma With Large Tumor Sizes > 3 cm.
    Jan HC; Hu CY; Yang WH; Ou CH
    Clin Genitourin Cancer; 2020 Aug; 18(4):e484-e500. PubMed ID: 32199741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer.
    Jang WS; Cho KS; Kim KH; Yoon CY; Kang YJ; Lee JY; Ham WS; Rha KH; Hong SJ; Choi YD
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):298-304. PubMed ID: 27349499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP).
    Kitagawa Y; Ueno S; Izumi K; Mizokami A; Hinotsu S; Akaza H; Namiki M
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):673-9. PubMed ID: 24522405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
    Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
    World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.